---
document_datetime: 2023-09-21 18:18:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/optison-epar-procedural-steps-taken-authorisation_en.pdf
document_name: optison-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4099405
conversion_datetime: 2025-12-22 17:09:24.272226
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Mallinckrodt  Medical  GmbH  submitted  on  26  February  1997  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Optison, through the centralised procedure. After agreement by the CPMP on 17 July 1996, this medicinal product was referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Prof. K Strandberg

Co-Rapporteur:

Dr. H. Pittner (replaced by Dr. C. Wirthumer)

## Licensing status

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 21 March 1997.
- The Rapporteur's first assessment report was circulated to all CPMP Members on 30 May 1997. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 2 June 1997.
- During the meeting on 22-23 July 1997 the CPMP agreed on the consolidated list of questions to be sent to the company. The final consolidated list of questions was sent to the Company on 23 July 1997
- The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  6  November 1997.
- The Rapporteur circulated the joint response assessment report on the company's responses to the list of questions to all CPMP Members on 17 December 1997.
- An updated joint assessment report was circulated to all CPMP members on 23 January 1998.
- The  company  submitted  a  letter  of  undertaking  dated  26  January  1998,  to  provide  further information relating to post-opinion followup measures, by the agreed deadlines. In this letter of undertaking, the company agreed that only those batches of albumin which have been tested and released  by  an  EU  national  control  authority  will  be  used  in  the  preparation  of  the  finished product.
- During the meeting on 26-28 January 1998 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Optison on 28 January 1998.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 18 May 1998.